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Background: CD8+ T cells recognize HIV-1 epitopes translated from a gene’s primary reading frame (F1) and any
one of its five alternative reading frames (ARFs) in the forward (F2, F3) or reverse (R1-3) directions. The 3’ end of
HIV-1’s proviral coding strand contains a conserved sequence that is directly overlapping but antiparallel to the env
gene (ARF R2) and encodes for a putative antisense HIV-1 protein called ASP. ASP expression has been demonstrated
in vitro using HIV-transfected cell lines or infected cells. Although antibodies to ASP were previously detected in patient
sera, T cell recognition of ASP-derived epitopes has not been evaluated. We therefore investigated the ex vivo and
in vitro induction of ASP-specific T cell responses as a measure of immune recognition and protein expression during
HIV-1 infection.
Results: A panel of overlapping peptides was initially designed from the full-length ASP sequence to perform a global
assessment of T cell responses. Recognition of ASP-derived antigens was evaluated in an IFN-γELISpot assay using
PBMCs from HIV-1 seropositive and seronegative individuals. Eight of 25 patients had positive responses to ASP antigens
and none of the seronegative donors responded. As a complimentary approach, a second set of antigens was designed
using HLA-I binding motifs and affinities. Two ASP-derived peptides with high predicted binding affinities for HLA-A*02
(ASP-YL9) and HLA-B*07 (ASP-TL10) were tested using PBMCs from HIV-1 seropositive and seronegative individuals who
expressed the matching HLA-I-restricting allele. We found that HLA-I-restricted ASP peptides were only recognized by
CD8+ T cells from patients with the relevant HLA-I and did not induce responses in any of the seronegative donors or
patients who do not express the restrictive HLA alleles. Further, ASP-YL9-specific CD8+ T cells had functional profiles that
were similar to a previously described HLA-A*02-restricted epitope (Gag-SL9). Specific recognition of ASP-YL9 by CD8+
T cells was also demonstrated by tetramer staining using cells from an HLA-A*02 HIV-infected patient.
Conclusion: Our results provide the first description of CD8+ T cell-mediated immune responses to ASP in HIV-1-infected
patients, demonstrating that ASP is expressed during infection. Our identification of epitopes within ASP has implications
for designing HIV vaccines.
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Thirty years after its appearance, the HIV/AIDS epi-
demic still represents a major public health threat world-
wide. Strategies for developing effective host immunity
and protection against HIV-1 infection or lifelong con-
trol of the virus are urgently needed. Multiples lines of
evidence suggest that HIV-specific cytotoxic CD8+ T
cells (CTLs) participate in controlling viral replication
[1-3]. During acute infection, the expansion of HIV-
specific CTLs occurs prior to the appearance of neutral-
izing antibodies and is associated with decreased viremia
[4,5]. Delayed disease progression has been correlated
with the detection of Gag-specific CTLs and the pres-
ence of protective human leukocyte antigen class I
(HLA-I) alleles, which effectively present HIV-1 derived
epitopes for immune recognition [6-10]. However, HIV
rapidly mutates to evade virus-specific T cell responses,
underlying the selection pressure exerted by CTLs
[11-13]. Thus, protection against HIV will likely require
a vaccine that affords immediate CTL recognition of in-
fected cells through sustained presentation of conserved
T cell epitopes.
CTLs are stimulated by peptides presented by MHC-I
molecules and generated from the proteolysis of all nine
proteins encoded by the three forward reading frames of
its sense mRNA strand. In addition to protein-derived
epitopes, investigations over the last two decades have
led to the discovery of cryptic epitopes, a novel set of
T cell targets translated from alternative reading frames
(ARFs) in both sense and antisense transcripts during
autoimmune disease, cancer and several viral infections,
including HIV-1 and SIV [14-26]. Moreover, sequence
analysis of HIV-1 clade B isolates have repeatedly detected
a conserved open reading frame in an ARF of env, suggest-
ing the existence of a possible tenth viral protein [27-32].
Vaquero et al. demonstrated in vitro that this antisense
ARF encodes a protein of 19kD, so called antisense pro-
tein (ASP) [33]. Subsequently, the existence of ASP has
been supported by its in vitro expression from a native up-
stream promoter and, shortly thereafter, the detection of
antibodies to ASP in patient sera [28,33,34]. Recently, we
and others have confirmed that ASP is expressed by several
cell types during HIV-1 infection [29,35-38]. Interestingly,
ASP was detected in monocyte-derived macrophages and
dendritic cells, which was consistent with preferential
transcription of the antisense strand in these antigen-
presenting cells (APC) [37]. Collectively, the aforemen-
tioned studies suggest that ASP is produced during the
viral cycle. We previously demonstrated that ARF-
derived HIV-1 antigens (i.e. cryptic epitopes, CE) are
produced during infection by detecting CE-specific
CTLs [17]. We therefore extended this work by evaluating
T cell recognition of ASP-derived antigens in HIV-1 sero-
positive patients.In an unbiased approach, we used pools of overlapping
ARF peptides spanning the entire length of ASP to de-
tect ASP-specific T cell responses in PBMCs obtained
from HIV-1 seropositive and seronegative donors. We
further investigated CD8+ T cell responses to predicted
HLA-I-restricted epitopes derived from ASP. Overall,
our findings show that ASP is specifically targeted by
CD8+ T cells of chronically infected patients, revealing
ASP as a HIV-1 antigen.
Results
ASP-overlapping peptides induce IFN-γ T cell responses in
HIV seropositive patients
Immune responses to ASP were first studied using
PBMCs from HIV-1 subtype B seropositive patients
(Pats.1 to 25, Additional file 1: Table S1) who were off
antiretroviral therapy (ART) and 10 seronegative donors
(SN). T cell responses were measured with an ex vivo
interferon gamma (IFN-γ)-ELISpot assay using a pool of
peptides encompassing the whole ASP sequence (85
peptides, 14-18-mers overlapping by 10). To increase the
likelihood of detecting CTL responses primed during
acute or chronic infection, the ASP pool included pep-
tides derived from the sequence of a transmitter founder
virus WITO_TF1 [39] and NL4-3, a viral strain isolated
during chronic infection and expressing ASP in infected
cells [29,33,37,38]. Within this cohort, 4 out of the 25
patients responded to ASP (Figure 1B, Pats.04, 19, 24,
25). A pool of peptides encompassing Gag was used as a
positive control and induced CTL responses in all pa-
tients. No ASP-specific or Gag-specific responses were
detected in any seronegative donors (Figure 1A). We
then analyzed T cell responses to 19 subpools of ASP,
containing 8 to 10 peptides (Additional file 2: Figure S1).
We observed that 6 patients (Figure 1B, Pats 04, 07, 09,
18, 19, 21) responded to one or two subpools of ASP
peptides and that a total of 6 different subpools induced
CTL responses (#7, B, D, E, H, I). Thereafter, two pa-
tients (Pats.04 and 19) responded to both the total pool
of ASP peptides as well as one or more subpools (sub-
pools #7 and B, E). Notably, Pats.24 and 25 responses to
subpools (G, H, J, and 9, respectively) tended to be posi-
tive though just under our stringent limit of positivity
(more than four times background but 45 SFU/106
PBMCs). Overall, the magnitude of T cell responses to
the ASP pool or subpools was significantly greater in
seropositive patients than in seronegative donors (p < 0.01;
Figure 1C). Overall, we found a high frequency of patients
responding to ASP antigens (32%; Figure 1D).
Identification of ASP-specific HLA-A*02 and –B*07-restricted
T cell responses
Our panels of OLP showed that HIV-1-specific IFN-γ
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Figure 1 HIV-1 ASP peptide pools activate IFN-γ T cell responses in a cohort of HIV+ individuals. The magnitude of IFN-γ ELISpot responses
(SFU/106 PBMCs) to the Gag or ASP pools and subpools (1 to 9, and A to J) are shown for (A) seronegative donors and (B) HIV-1+ patients. Each dot
represents one donor and mean IFN-γ responses of triplicate or quadruplicate are indicated. The dashed line marks the standardized threshold
(55 SFU/106 PBMCs) for positivity. (C) PBMCs were assessed for IFN-γ production using ASP pools and 19 ASP subpools. Mann–Whitney U
tests were performed to determine significant differences between the median responses to peptide pools (p < 0.01). (D) The frequency of responders
is illustrated as a proportion of seronegative (SN) or seropositive (HIV+) individuals with positive responses to the Gag pool (blue column) and either to the
ASP pool or any ASP subpool (red column).
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consistently identify individual epitopes or peptides that
could contain them. However, the analysis was performed
using 14-18-mer peptides for global sequence coverage of
the ASP protein and may have provided suboptimaltargets for CD8+ T cells, which recognize MHC-I mol-
ecules presenting 8-11-mer peptides. We therefore in-
vestigated ASP-specific T cell responses using a common
“reverse immunology” approach [17]. In brief, potential
ASP-derived peptides with high affinity to a specific
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these candidates was evaluated in HLA-I-matched indi-
viduals. The analysis of HIV-1 clade B and M sequences
revealed two peptide sequences, ASP-YL9 (YLYNSLLQL)
and ASP-TL10 (TPNGSIFTTL), with high binding scores
to HLA-A*02 and HLA-B*07 molecules, respectively
(Additional file 3: Table S2). In comparing the conser-
vation of classical epitopes and ASP peptides, both
ASP peptides had classical equivalents that were either
poorly (e.g. ASP-TL-10 and Gag-YF10) or highly (e.g. ASP-
YL9 and Env-KL9) conserved [40-42]. To increase the
probability of detecting HLA-I-restricted CTL responses
to ASP, the ASP-YL9 and ASP-TL10 peptides were se-
lected for use in immunoassays based on their high HLA-
binding score and relative conservation. T cell responses
against these peptides were investigated within a cohort of
HIV-1 seropositive donors (Pats.32 to 126, Additional
file 1: Table S1). PBMCs were screened for HLA-A*02
and HLA-B*07 alleles expression by antibody staining.
PBMCs from 49 HLA-*02+ patients (Pats.32 to 74, 98
to 103) were assayed for ex vivo IFN-γ ELISpot responses
against the ASP-YL9 peptide. A known HIV-derived
HLA-A*02-restricted epitope (Gag-SL9) and an HCV-
derived irrelevant peptide were used as positive and
negative controls (NC), respectively (Figure 2A). Four
patients (Pats.34, 42, and 43 and 100) responded to
ASP-YL9. Magnitudes of ASP-specific T cell responses
ranged from 114 to 307 SFU/106 PBMCs and were
weaker than Gag-SL9 responses (92 to more than 1000
SFU/106 PBMCs). Strikingly, no responses against ASP-
YL9 were detected in HLA-A*02+ HIV-1 seronegative do-
nors and in HLA-A*02 negative patients (n = 30, Pats.89
to 95, 104 to 126). Height percent of PBMCs from HLA-
A*02+ seropositive donors were activated by ASP-YL9
(Figure 2B). We then assessed ex vivo IFN-γ responses
against the ASP-TL10 peptide. We used a pool of three
known HLA-B*07-restricted Gag epitopes (pool named as
“Gag-B7”) and a CMV-derived HLA-B*07-restricted epi-
tope (pp65) as positive controls. Twenty-seven HLA-
B*07+ patients were tested (Pats.69 to 88, 104 to 110)
and three individuals (Pats.78, 79 and 108) positively
responded to the ASP-TL10 antigen (average magni-
tude of responses of 98 SFU/106 PBMCS) (Figure 2C).
No ASP-TL10-specific T cell responses were found
within the HLA-B*07+ seronegative donors and HLA-
B*07 negative HIV patients (n = 27, Pats.66 to 68; 96 to
103, 111 to 126). Eleven percent of PBMCs from HLA-
B*07+ seropositive donors were activated by ASP-TL10
(Figure 2D). Taken together, the frequency of responders
to ASP-YL9 or ASP-TL10 was lower than the proportion
of patients who responded to immunodominant Gag-
derived antigens: 16% of HLA-A*02+ patients responded
to Gag-SL9 and 37% of HLA-B*07+ patients responded to
Gag-B7.ASP-specific CD8+ T cells produce multiple cytokines and
chemokines
Recognition of 8-11-mer peptides by T cell receptors of
CD8+ T cells requires presentation of these antigens by
HLA-I molecules. To assess whether CD8+ T cells
recognize the ASP-Y9L peptide, we analyzed production
of intracellular cytokines in a flow cytometry assay (ICS)
following stimulation of PBMCs from 11 HLA-A*02+
patients (Pats.32 to 42), and one HLA-A*02- patient as
control (Pat.95). Cells were pulsed with the ASP-YL9
peptide. Production of MIP1-β or IL-2, TNFα and IFN-γ
together was assessed on CD8+ cells (Figure 3A). We
measured the proportion of activated cells producing at
least one of these cytokines/chemokines upon peptide
stimulation (Figure 3B). 0.1% of CD8+ T were specific-
ally stimulated by ASP-YL9 for two HLA-A*02+ patients
(Pats.34 and 42). No ASP-specific stimulation of CD8+
T cells was observed for Pat.95 (HLA-A*02-). Induction
of Gag-SL9-specific CD8+ T cells was also detected in
three patients, including Pats.34 and 42 (range, 0.1 to
0.3% of CD8+ T cells). The results strongly suggest that
the IFN-γ detected in our previous ELISpot assays was
secreted by CD8+ T cells (Figure 2A, B). We then evalu-
ated whether ASP-specific CD8+ T cells were producing
multiple cytokines together (Figure 3C). 97% of ASP-
YL9-specific CD8+ T cells were producing IL-2, IFN-γ
or TNFα, together with a production of MIP1-β for 80%
of them (Figure 3D, black pie). Thus, epitope-specific
CD8+ T cells produce multiple cytokine/chemokines
upon recognition of ASP-YL9. This subset exhibits a
functional profile similar to Gag-SL9-specific CD8+ T
cells, with a majority of cells producing multiple cyto-
kine/chemokines at the same time (Figure 3D). Although
the measurable cytokines are not evidence of T cell-
mediated cytotoxicity, the capacity of ASP-specific CD8+
T cells to produce multiple cytokines/chemokines possibly
enhances their ability to kill HIV-1-infected cells [43,44].
Identification of ASP-YL9-specific CD8+ T cells by tetramer
staining
We further examined the antigen specificity of CD8+ T
cell responses in a subset of participants (Pats.26 to 31).
We previously showed that magnitude of HIV-1 ARF-
specific CD8+ T cell responses are increased following
in vitro stimulation of PBMCs with antigens [45]. PBMCs
from HLA-A*02+ HIV+ patients and seronegative control
donors (SN) were expanded with the ASP-YL9 peptide
and stained with an ASP-YL9/HLA-A*02 tetramer. When
PBMCs from Pat.28 were analyzed, 0.11% of CD8+ T cells
were stained specifically with the HLA-A*02/ASP-YL9
tetramer, corresponding to 0.06% of the total T cell popu-
lation (Figure 4A, B). In contrast, no specific staining
could be detected within the CD4+ T cell population
(Figure 4A). No tetramer staining was detected in other
A B SN HIV+ 




















































































































































































































































Figure 2 HLA-I-restricted ASP epitopes are recognized by CD8+ T cells during HIV-1 infection. (A) PBMCs isolated from HIV-1 seropositive
patients and seronegative donors were stimulated ex vivo with ASP-YL9 in an IFN-γ ELISpot assay. An HCV irrelevant and HIV Gag-derived
HLA-A*02-restricted (Gag-SL9) peptide was used as negative and positive controls, respectively. Dotted line indicates a mean threshold of
peptide responders (4 times background, 90 SFU/106 PBMCs). Four HLA-A*02+ HIV+ patients had responses to ASP-YL9 (n = 49, right panel),
whereas no IFN-γ secretion was detected in HLA-A*02- HIV+ patients (n = 30, middle panel) or HLA-A*02+ seronegative donors (SN, n = 7,
left panel). (B) Frequencies of ASP-YL9-, or Gag-SL9- responders according to each group are shown. (C) As in (B) with the ASP-TL10 peptide
and a CMV-derived (pp65) peptide. Three HLA-B*07+ HIV+ donors were responding to ASP-TL10 (n = 27, right panel), whereas no responses
were detected in HLA-B*07- seropositive donors (n = 27, middle panel) and HLA-B*07+ SN (n = 5, left panel). (D) Frequencies of donors
responding to ASP-TL10, HIV Gag (Gag-B7) or CMV (pp65) are indicated according to each group.
Bet et al. Retrovirology  (2015) 12:15 Page 5 of 13patients and seronegative donors. Together, these results
indicate that the ASP-YL9 peptide elicits HLA-A*02 re-
stricted CD8+ T cells during HIV infection.
Discussion
The existence of a tenth HIV-1 protein encoded by gen-
omic plus strand has been suggested since the late 80s
[27]. Yet, in vivo antisense transcription and translation
of not only HIV-1, but also of other retroviruses, hasremained a topic of debate. In this study, we show that
CD8 T cell responses to an antisense derived HIV pro-
tein (ASP) are detected during chronic HIV infection.
Further, we demonstrate that these ASP specific CD8 T
cells have comparable functionality to the traditional
protein-derived HLA-I restricted epitopes.
Virological but also immunological attributes of anti-
sense proteins were emphasized by HBZ and APH-2,
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Figure 3 The HIV-1 ASP-YL9 peptide activates CD8+ T cell responses. Intracellular cytokine staining (ICS) was used to analyze CD8+ T cell
responses to ASP-YL9 in 11 HLA-A*02+ patients (Pats.32 to 42) and one HLA-A*02- patient (Pat.95). (A) Flow cytometry analysis from Pat.34,
illustrating MIP1-β versus IL-2/TNFα/IFN-γ production by CD8+ cells after HCV- (negative control, NC), HIV ASP-YL9 or HIV Gag-SL9 stimulation.
(B) Frequencies of CD8+ cells producing at least one of the analyzed cytokine/chemokine. Pats. 34 and 42 were activated upon ASP-YL9 stimulation.
(C) For these two patients, percentages of Gag-SL9 (blue) or ASP-YL9 (red) stimulated CD8+ cells, producing either only MIP1-β (white), only IL-2/
TNFα/IFN-γ (grey), or both chemokines/cytokines panels (black) were analyzed. NC background was subtracted and average percentages (±SD) from
Pats.34 and 42 analysis are presented. (D) Pies indicate relative proportions of Gag-SL9 or ASP-YL9 activated CD8+ T cells producing each panel of
cytokines/chemokines (presented in C).
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spectively [46-48]. HBZ modulates viral transcription,
persistence of the virus and infectivity. It may also play a
role in induction of cellular immune responses control-
ling the virus [49]. Thus, antisense proteins appear crit-
ical for understanding retroviral pathogenesis. The role
of antisense transcripts from HIV-1 still remains poorly
studied. Their existence was demonstrated in vitro and
in the context of infection [32,50]. Conservation of the
antisense reading frame directed investigations to search
for a protein translated by these antisense transcripts
[27,35,38]. Vaquero et al. demonstrated that antibodies
from sera of seropositive individuals were detecting ASP
[33]. Evidence of the expression of ASP was further con-
firmed by in vitro experiments [29,34,37]. Although allthese approaches stressed the fact that ASP is expressed
during infection, studies have not convinced the scien-
tific community of the existence of this protein. In the
present study, we revisited this question by investigating
the induction of ASP-specific CD8+ T cells in patients
after HIV-1 infection. Our results show for the first time
that a proportion of HIV-specific CD8+ T cells are tar-
geting ASP and are activated during chronic infection.
Over the last three decades, the pool of HIV-1 CTL
epitopes has been studied extensively. CTLs target epi-
topes from all nine structural and regulatory proteins
encoded by open reading frames in the RNA sense
strand. Alternative translation of retroviral genes was
initially hypothesized in mice infected by LMP5, an
immunodeficiency-causing retrovirus [51]. Green and
AB
Figure 4 Detection by tetramer of HLA-A*02-restricted, ASP-YL9-specific CD8+ T cells in HIV+ patients. Following in vitro restimulation of
PBMCs with ASP-YL9 peptide, cell lines from 6 HLA-A*02+ HIV+ patients (Pats. 26 to 31) and 4 HLA-A*02+ seronegative donors (SN 1 to 4) were
stained for CD4 and CD8 in combination with the HLA-A*02/ASP-YL9 tetramer. (A) Gating strategies and illustration of tetramer staining for SN2,
Pat.28 and Pat.29. In Pat.28, 0.06% tetramers + cells were detected corresponding to 0.11% of CD8+ T cells. No tetramer + cells were detected
among CD4+ cells. In Pat.29, no significant tetramer+ population was detected (Fisher-exact test). (B) Percentages of HLA-A*02/ASP-YL9 tetramer
+ cells within CD8+ T cells of HIV+ patients and seronegative donors.
Bet et al. Retrovirology  (2015) 12:15 Page 7 of 13
Bet et al. Retrovirology  (2015) 12:15 Page 8 of 13colleagues expanded the known pool of T cell targets by
demonstrating that CTL epitopes were generated in vivo
from translation of a gag ARF, rather than the gene’s pri-
mary reading frame. ARF-derived antigens, often smaller
in size than traditional proteins, appear labile and diffi-
cult to detect by conventional approaches. Nevertheless,
the incredible sensitivity and specificity of CTLs allows
for efficient detection of cryptic epitopes (CE) from
ARFs. CTLs targeting CE of HIV-1 and SIV have been
detected by several groups, thus revealing the translation
of sense and antisense ARFs [15-17,52,53]. CTLs target-
ing CE are elicited during infection following stimulation
by antigen-presenting cells. Further, mutations within
these CE can arise in order to escape CTL responses
[11,53]. All of these findings strongly suggest that ARF
sequences are translated during the viral cycle and sub-
sequently recognized by the immune system. Here, we
demonstrated that ASP-specific CD8+ T cells were de-
tectable in the blood of seropositive individuals by com-
bining two complementary approaches. Strikingly, no
epitope-specific T cell responses were detected in sero-
negative donors or in HIV+ patients who did not carry
the appropriate HLA-I alleles. Peptides from various lo-
cations within ASP were recognized. Our results indicate
that the full-length ASP protein is likely processed and
presented by MHC-I molecules. Since ASP-specific CD8+
T cells are generated in infected individuals during the
course of HIV-1 infection, our results strongly suggest
that ASP is expressed by infected cells and constitutes a
source of antigens for inducing CD8+ T cell responses, ei-
ther following natural infection or vaccination.
In our unbiased approach, approximately 30% of the
donors showed positive IFN-γ responses to ASP, whereas
the response level to individual peptides ASP-YL9 and
ASP-TL10 were detected in 8% of HLA-A*02+ donors
and 11% of HLA-B*07+ donors, respectively. The pro-
portion of responses to pool and subpools may have
been higher than the proportion of responses to optimal
peptides because pools include a greater number of pep-
tides, thus increasing the likelihood of activating ASP-
specific CTLs with various antigenic specificities. Our
lead hypothesis was that ASP is expressed during infection
and induces CD8+ T cell responses. However, whether
ASP is expressed during acute and/or chronic infections
remains to be determined. Thereafter, we thought that in-
cluding peptides overlapping WITO_TF1 sequence might
increase the chance to activate CTL responses primed dur-
ing the early step of acute infection. In addition, NL4-3,
that was used to design the set of peptides overlapping a
viral strain isolated during chronic infection, was selected
because we have previously shown that NL4-3-infected
cells express ASP [29,37,38]. WITO_TF1 and NL4-3 might
not be representative of the circulating virus present in the
tested patients but allowed us to maximize our chance todetect CTL responses. Obviously, it would be of great
interest to sequence the quasi-species circulating in the
blood of patients to study the conservation of ASP ORF
and amino acid sequences with regards to ASP-specific
CTL responses.
As majority of our patients were treated, the frequency
of ASP responders was doubtlessly underestimated. ART
may impact the magnitude and the breadth of ASP-
specific CTL responses, as demonstrated for ARF sense
and antisense epitopes [54]. The magnitude of T cell re-
sponses to ASP appear weak but were significantly
higher that non-specific responses from seronegative do-
nors. Although responses to the ASP peptide pool and
subpools did not exceed to 100 SFU/106 PBMCs, ASP-
YL9 responses reached 300 SFU/106 of PBMCs. The
capacity of peptide pools to activate T cell responses was
evaluated using cryopreserved PBMCs, whereas fresh
PBMCs were used to detect ASP-YL9 and ASP-TL10 re-
sponses. Although the magnitudes of CTL responses
might have been stronger using fresh samples, using fro-
zen cells, we readily detected ASP-specific CTL responses.
Magnitudes of ASP-specific responses from ex vivo
PBMCs are in fact consistent with previous analyses for
responses to cryptic epitopes from ARFs [15-17,45]. How-
ever, the limited magnitude of T cell responses may be
due to low expression of these antigens, poor MHC-I
binding and presentation, or a T cell repertoire with a low
affinity for these antigens. Indeed, in contrast to Gag,
cryptic epitopes are produced by non-conventional mech-
anisms of translation of the viral genome. To our know-
ledge, events responsible for protein synthesis from ARF
of transcripts and mechanisms regulating this process are
not clearly defined. The transcription factors NFκB and
Sp1 but not the HIV-1 Tat protein are positive modulators
of HIV antisense transcription [55]. Antisense RNA ap-
peared preferentially transcribed in specific cell-types (e.g.
monocyte-derived cells) [37]. ASP potentially induces au-
tophagy [38]. Thus, various parameters may justify pre-
sumed low abundance of ASP in infected cells, and
therefore a weak induction of CTL responses. HIV-specific
CTLs conferring protection to patients have been shown
to have a high sensitivity to antigen, develop multiple anti-
viral functions and have non-exhausted phenotype [56]. In
our approach, we showed by intracellular staining that pro-
duction of cytokine/chemokines by ASP-specific CTLs ap-
pears as diverse as for conventional CTLs (Gag-SL9). The
quality of ASP-specific CTLs responses, their phenotypes
and capacity to control infection remains to be defined.
We focused our explorations on individuals expressing
HLA-A*02 or HLA-B*07, two alleles frequent among
the Caucasian population and whose peptide anchor
motifs are well defined. These alleles are not associated
with a delayed disease progression. It would be of inter-
est to analyze ASP-specific CTL responses in patients
Bet et al. Retrovirology  (2015) 12:15 Page 9 of 13that spontaneously control the infection but also in
post-treatment controllers [57]. Current vaccines do not
prioritize the expression of ASP or epitopes from this
ARF. Harnessing the strategic engineering and control of
HIV-1’s genetic code in the context of a highly efficient
vector has the potential to increase production and pres-
entation of viral immunogens following vaccination. Im-
portantly, the number of vector-derived immunogens
could be increased through constructs that express both
sense and antisense reading frames, thus inducing broader
immune responses to protein- and ARF-derived epitopes
without expanding the size of the vector insert [5,58-63].
In fact, vector-derived cryptic epitopes encoded by anti-
sense gag and pol ARFs have been shown to induce HIV-
1-specific T cell responses in vaccinees who participated
in a Phase 2b trial (HVTN 205). This suggests that current
MVA/DNA vaccines encoding the env region may already
induce ASP-specific CD8+ T cell responses [45].
Conclusions
Our data demonstrated for the first time that epitope-
specific CD8+ T cells from infected individuals target
ASP. Moreover, the ex vivo induction of ASP-specific
CD8+ T cell responses provides strong evidence of ASP
expression during infection, thereby supporting ARFs as
an additional source of HIV-1 immunogens. Future
studies assessing the functionality of ASP and other con-
served ARF sequences will therefore be critical for enhan-




Two cohorts of HIV infected patients were studied.
First, peripheral blood mononuclear cells (PBMCs) were
collected from US patients with HIV-1 clade B infections
(Additional file 1: Table S1, Pat 1 to 25) and seronegative
donors (n = 10). All HIV seropositive patients were off
ART and, with a median CD4 T cell count of 789 cells/μL
(range, 449 – 1176 cells/μL), median CD4 nadir of 434
cells/μL (range, 116 – 827 cells/μL), and median plasma
viral load (VL) of 616 RNA copies/mL (range, 21 – 16,400
RNA copies/mL). HLA class I alleles were typed to
two- or four-digit specificity by PCR amplification
using sequence-specific primers as described before [64].
Second, PBMCs were collected from HIV-1 positive
HCV (Hepatitis C virus) negative patients from a French
ANRS cohort (Additional file 1: Table S1, Pats. 26 to
126) [65]. Ninety-two percent of these patients were on
ART (range, 0.5 - 26 years). Twenty-five percent of all
patients had a detectable viral load (range, 21–2,951,507
RNA copies/mL) and the median CD4 T cell count was
522 (range, 18 – 1854 cells/μL). All patients were chronic-
ally infected and 8 were recently detected as seropositive(Pats. 26, 42, 50, 70, 87, 100, 107, 126). HLA types were
first determined by FACS analysis using anti-HLA*07
(BB7.1, AbD Serotec) and anti-HLA-A*02 (BB7.2, Biole-
gends) antibodies. HLA-B*07+ and HLA-A*02+ cell lines
were simultaneously analyzed as positive controls. HLA
status of ASP responders was further confirmed by geno-
typing using PCR or using the Luminex xMAP technology
[66,67]. PBMCs from HIV-1–seronegative control donors
were purchased from the Etablissement Français du Sang
of the Pitié-Salpêtrière Hospital (Paris, France).
Demographic, HLA-typing, virological and clinical char-
acteristics of patients included in both cohorts are shown
in Additional file 1: Table S1.Ethics statement
All samples were obtained according to protocols ap-
proved by the Institutional Review Board (IRB) at the
University of Alabama at Birmingham. Patient samples
were collected according to French Ethical rules. Writ-
ten informed consent and approval by institutional review
Board at the Pitié-Salpêtrière Hospital were obtained.Antigen design
Consensus clade B 15-mer peptides (123 total) overlap-
ping by 11 amino acids (aa) for HIV-1 Gag were ob-
tained through the NIH AIDS Reagent Program (catalog
#8117). In our unbiased approach, we used ASP se-
quences obtained from the transmitted founder virus of an
acute patient (WITO_TF1, Genbank Acc.# JN944938.1)
and a HIV-1 lab strain, NL4.3 (Genbank Acc.# M19921),
to design 85 overlapping ASP peptides (OLPs; 14 to
18mers overlapping by 10 residues) using the Los Alamos
National Lab’s PeptGen tool (http://www.hiv.lanl.gov/con-
tent/sequence/PEPTGEN/peptgen.html; Additional file 2:
Figure S1). Peptides were synthesized in a 96 well array for-
mat by New England Peptide [68]. Individual OLPs were
combined into a single Gag or ASP pool. ASP subpools of
no more than 10 peptides were used in a matrix format.
Peptides were reconstituted in 100% DMSO at 40 mM/pep-
tide. Working stocks were prepared with water to a final
concentration of 100 μM/peptide. The final concentration
during the ELISpot assay was 5 μM/peptide in 100 μl, corre-
sponding to ≤1% and ≤0.1% of DMSO (v/v) for the total
pools (ASP and Gag) and ASP subpools, respectively.
As a complementary strategy, HLA-I binding affinities
and associations of potential ASP epitopes were evalu-
ated using BIMAS, SYFPEITHI and NetMHC prediction
algorithms (Additional file 3: Table S2) [69-71]. Two epi-
topes were synthesized, YLYNSLLQL (ASP-YL9) and
TPNGSIFTTL (ASP-TL10) (Proimmune). Peptides were
selected based on high binding affinities for HLA-I al-
leles HLA-A*02 and HLA-B*07 respectively, and on the
other hand on their conservation among HIV-1 strains.
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Ex vivo IFN-γ ELISpot assay
In the unbiased approach using OLP, cryopreserved
PBMCs were thawed and rested overnight at 37°C, 5%
CO2 in RPMI containing 5% human serum and supple-
mented with penicillin, streptomycin, and L-glutamine.
Interferon gamma ELISpot assays were performed as
previously described using a total pool containing all
peptides, subpools, or individual peptides [15,45]. Anti-
gens were tested in duplicate or triplicate with 100,000
PBMCs/well in nitrocellulose 96-well plates precoated
overnight with anti-IFN-γ coating antibody and un-
stimulated cells were plated in quadruplicate as a nega-
tive control; phytohemagglutinin (PHA) was tested in
duplicate as a positive control. Spot forming units (SFU)
were counted by an ELISpot reader (ImmunoSpot; CTL)
as a measure of cytokine production.
In the approach using optimal peptides, ex vivo
ficoll-isolated PBMCs were stimulated by 1 μM syn-
thetic peptides in IFN-γ ELISpot assays as previously
described [72]. An HCV-derived epitope (GPRLGVRAT)
was used as negative control (NC), and a CMV-derived
epitope (pp65 417TPRVTGGGAM426) as positive control
for HLA-B*07 donors. Known HIV-1- Gag-derived epi-
topes were used to test HIV reactivity, either a pool
(Gag-B7) of three HLA-B*07-restricted epitopes (Gag-SV9,
p24 16SPRTLNAWV24, Gag-TL9, p24 48TPQDLNTML56,
Gag-YF9, p2p7p1p6 121YPLASLRSLF130) or an HLA-A*02-
restricted epitope (Gag-SL9, p17 77SLYNTVATL85) [41,73].
T cell responses were reported as positive if i) the
mean response to the sample’s negative control was in-
ferior to 30 SFU/106 PMBCs, ii) the average response
was more than 55 SFU/106 PMBCs, iii) greater than 4
times the mean response to the sample’s negative con-
trol, iv) greater than the mean response to the sample’s
negative control plus 3 standard deviations, and v) the
mean response to the sample’s positive control (PHA)
was greater than 500 SFU/106 PBMCs [74].
Intracellular cytokine staining (ICS) assay
Ex vivo isolated PBMCs from 11 HLA-A*02+ and 1
HLA-A*02- HIV donors were rested overnight in RPMI
1640 supplemented with 5% human serum (Institut Jac-
ques Boy), 2 mM L-glutamine, 100 IU/mL penicillin,
100 μg/mL streptomycin, 10 mM Hepes, 1% nonessen-
tial amino acids, 1 mM sodium pyruvate. Cells were
pulsed with individual peptides (1 μM) for 2 hours at 37°C
and brefeldin A (5 μg/mL; Molecular Probes) was added
for 6 hours at 37 °C. Cells were fixed, permeabilized, and
stained using standard procedures with CD8-APC (RPA-
T8), TNFα-PE (MAb11), IL-2-PE (MQ1-17H12), IFN-γ-PE
(B27) (BD Pharmingen), and MIP-1β-FITC (24006, R&DSystems). Cells were analyzed with a FACS-Calibur™ cyt-
ometer (BD Biosciences). Flow cytometry data were ana-
lyzed with FlowJo software (Tree Star).
In vitro expansion of ASP-specific CD8+ T cells
Cryopreserved PBMCs from 6 HIV-1+ patients and 4
seronegative donors with HLA-A*02 alleles were pulsed
with the ASP-YL9 peptide (1 μM) and cultured for 7 days
in the presence of IL-2 (100 IU/mL; Miltenyi). On day 3,
20 ng/ml recombinant human IL-7 (Sanofi-Synthelabo)
was added. Samples were then evaluated for antigen spe-
cificity in a flow cytometry-based assay using anti-CD4-
APC-Cy7 (RPA-T4, BD Pharmingen), anti-CD8-APC
(RPA-T8 BD Pharmingen), and PE-conjugated HLA-
A*02 tetramers presenting the ASP-YL9 peptide (TC
Metrix). Cultured cells were incubated in PBS 0.5%
BSA (Sigma) with tetramers and antibodies for 20 min
at 4°C, then washed and fixed before measuring the
frequency of single CD4- tetramer + CD8+ T cells for
each participant with a BD FACS Canto cytometer.
Statistical analysis
T cell responses were analyzed for differences in magni-
tude using two-tailed non-parametric Mann–Whitney
U tests calculated by GraphPad Prism v6.0b and fre-
quency comparisons were done using two-tailed Fish-
er’s exact tests calculated by GraphPad QuickCalcs,
where p values of 0.00001 or less were considered sta-
tistically significant. A high-powered statistical test and
an adjusted significance threshold were applied to strin-
gently assess small differences between large sample sizes
(total number of subset and gated events) and Type I
errors.
Additional files
Additional file 1: Table S1. Demographic, HLA-typing, virological and
clinical characteristics of patients.
Additional file 2: Figure S1. Antigens designed for detection of
epitope-specific T cell responses provide global sequence coverage of
HIV-1 ASP. (A) Overlapping peptides were designed using ASP sequences
isolated from transmitted founder virus of an acute patient (WITO_TF1,
red) and a HIV-1 lab strain (NL4-3, green). Peptides encoded by both
strains are indicated in purple. Amino acid differences between peptides
are highlighted in bold. Translated sequences are shown in the 5’ to 3’
direction, corresponding to the N- and C-termini of ASP, respectively.
Sequences for ASP-YL9 and ASP-TL10 peptides are boxed. ni: not included,
if the peptide could not be synthesized or did not pass NEP’s quality control
standards. (B) Matrix design for subpools ASP peptides (A to J, and 1 to 9).
Peptide number refers to the peptides listed in (A). Patients responding to
peptide subpools are indicated along the x- and right y-axis.
Additional file 3: Table S2. Binding affinity and conservation of
HLA-A*02- and HLA-B*07-restricted HIV-1 epitopes.
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